Inclusion Criteria:  Being cis-gender male per self-identification Aged 18-35 years In good physical health, as determined by the site investigator or designee based on clinical history Willing and able to comply with study procedures and attend follow-up visits over 1 year Fluent in English, Xhosa, or Zulu Sexually active, defined by receptive or insertive anal or vaginal intercourse at least once a month in the past 3 months Able and willing to comply with all study procedural requirements Able and willing to provide informed consent Intention to stay within study catchment area for study duration and willingness to give adequate locator information At Screening and Enrollment, states a willingness to refrain from participation in other research studies involving drugs, vaccines, or medical devices during study participation. Participation in other behavioral studies is subject to Investigator discretion.  Exclusion Criteria:  Known or suspected allergy to study product components (active or placebo), including egg or soy products (egg and soy products are contained in Intralipid). At Screening or Enrollment, has a positive HIV test.  Diagnosed or suspected STI requiring treatment at Enrollment such as gonorrhea (GC), chlamydia, trichomonas, and/or syphilis. Enrollment will be considered after treatment of STIs.  Note: Genital warts requiring treatment and frequent recurrence of herpes simplex virus (HSV) are considered exclusionary; however, infrequent HSV outbreaks are not. Genital warts requiring treatment are defined as those that cause undue burden or discomfort to the participant, including bulky size, unacceptable appearance, or physical discomfort.  As determined by the Investigator/designee, any current or historical physical or mental health condition that the site investigator or designee determines should exclude participation (for example, injection drug use within the past year). Has any other condition that, in the opinion of the Investigator/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. At Enrollment, participant reports current or recent (30 days or less prior to enrollment) participation in any research study involving drugs, vaccines, or medical devices. Allowance for co-enrollment in other types of studies is indicated below.